Page last updated: 2024-12-08

bacteriochlorin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isobacteriochlorin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bacteriochlorin a: photosensitizer agent in photodynamic therapy; RN given refers to (7S-(7-alpha,8beta,17beta,18alpha))-isomer; RN for cpd without isomeric designation not avail 9/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18725796
CHEBI ID52583
SCHEMBL ID335767
SCHEMBL ID335765
MeSH IDM0179919
PubMed CID159279
MeSH IDM0179919

Synonyms (14)

Synonym
isobacteriochlorin
2,3,7,8-tetrahydroporphyrin
CHEBI:52583
SCHEMBL335767
SCHEMBL335765
67883-10-7
21h,22h-porphine, 12,13,17,18-tetrahydro-
Q27123500
a bacteriochlorin
2,3,7,8,23,24-hexahydroporphyrin
bacteriochlorin a
103428-20-2
(7r,8r,17s,18s)-12-acetyl-18-(2-carboxyethyl)-20-(carboxymethyl)-7-ethyl-3,8,13,17-tetramethyl-7,8,17,18,21,23-hexahydroporphyrin-2-carboxylic acid
21h,23h-porphine-7-propanoic acid, 13-acetyl-3-carboxy-5-(carboxymethyl)-18-ethyl-7,8,17,18-tetrahydro-2,8,12,17-tetramethyl-, (7s-(7alpha,8beta,17beta,18alpha))-

Research Excerpts

Overview

Bacteriochlorin a (BCA) is a potential photosensitizer for photodynamic therapy of cancer. It is effective in tumour destruction upon illumination with light of a wavelength of 760 nm.

ExcerptReferenceRelevance
"Bacteriochlorin a (BCA) is a potential photosensitizer for photodynamic therapy of cancer. "( Effect of aggregation on bacteriochlorin a triplet-state formation: a laser flash photolysis study.
Damoiseau, X; Fontaine-Aupart, MP; Hoebeke, M; Tfibel, F, 2002
)
2.06
"Bacteriochlorin a (BCA) is a second-generation photosensitizer that is effective in tumour destruction upon illumination with light of a wavelength of 760 nm. "( Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases.
Rovers, JP; Schuitmaker, JJ; Terpstra, OT; Vahrmeijer, AL; van Dierendonck, JH, 1998
)
1.97
"Bacteriochlorin a (BCA) is an effective second-generation photosensitizer both in vitro and in vivo. "( Mutagenicity and dark toxicity of the second-generation photosensitizer bacteriochlorin a.
Bos, RP; Nagelkerke, JF; Schuitmaker, JJ; Vogel, EW, 1998
)
1.98

Compound-Compound Interactions

ExcerptReferenceRelevance
" When m-THPC PDT was combined with mitomycin C (MMC), light doses could be decreased by a factor of 2 for equal tumour effects."( Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.
Oppelaar, H; Oussoren, YG; Schuitmaker, JJ; Stewart, FA; van Geel, IP, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (43.75)18.2507
2000's12 (37.50)29.6817
2010's4 (12.50)24.3611
2020's2 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.08 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]